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Case Report 
Graves' Disease Associated with Goserelin Acetate 
Shigeki MORITA, Yasuo UEDA 
Internal Medicine, Japanese Red Cross-Nagasaki Atomic Bomb Hospital
 We describe a case of Graves' disease associated with 
goserelin acetate. A 47-year-old woman experienced 
thyrotoxicosis during the administration of goserelin ace-
tate, a gonadotropin-releasing hormone (GnRH) -agonist. Since 
the TSH receptor-antibody was positive, and a thyroid 
scintigram showed diffuse goiter and high uptake, she was 
diagnosed as having Graves' disease. 26 months after treat-
ment with thiamazole, she recovered. We speculate that the 
administration of goserelin acetate may be one of the trig-
gers of Graves' disease. 
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Introduction 
 The syndromes of thyroid autoimmunity, including 
Graves' disease and painless thyroiditis, can be in-
duced by genetic and environmental factors'-". It has 
been reported that many environmental factors, for 
example iodine, infection, glucocorticoids, postpartum, 
cytokines and also sex hormones can alter the 
immunologic tolerance of the thyroid gland and influ-
ence thyroid autoimmunity 3 - 5 
 Gonadotropin-releasing hormone(GnRH)-agonists are 
recently used for the treatment of sex hormone-
dependent diseases, for example mammary cancer and 
uterine myoma 6' , as the administration of GnRH 
agonists can alter the secretions of gonadotropin and 
sex hormones. It was suggested that GnRH agonists 
via sex hormones may be one of the triggers of the 
syndromes of thyroid autoimmunity" 8'. 
 Goserelin acetate is one of the GnRH agonists "°' . 
Here, we describe a case of Graves' disease associated 
with the administration of goserelin, and briefly re-
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view the literature of GnRH agonist-induced thyroid 
autoimmunity.
Case report 
 The patient was a 47-year-old woman who had pre-
viously undergone a mastectomy for left mammary 
cancer (positive for estrogen and progesterone rece-
ptors) in April 1996, and had been injected with 
3.6mg goserelin acetate every 4 weeks since that time. 
In May 1997, she exhibited general malaise, palpita-
tions and hand tremors. She was admitted on June 
19th, 1997. She had consumed no excess iodine in 
food, medicine or contrast media, and had taken no 
thyroid hormones. A physical examination on admis-
sion revealed tachycardia, hand tremors and diffuse 
goiter without exophthalmos. Serum concentrations of 
free thyroxine, free triiodothyronine and thyroid 
stimulating hormone were 4.0 ng/dl, 12.9 pg/ml and 
less than 0.05 p IU/ml, respectively. The serum level 
of anti-thyroid peroxidase-antibody was positive (1: 
1600), and that of anti-thyroglobulin-antibody was 
negative. The anti-TSH receptor-antibody (TRAb) was 
positive (52%). A Tc-99m thyroid scintigram showed 
diffuse goiter and high uptake, and she was diagnosed 
with Graves' disease. Thiamazole was administered for 
26 months and TRAb became negative (0%). After the 
cessation of thiamazole in September 1999, serum con-
centrations of thyroid hormones remained within nor-
mal levels.
Discussion 
 It has been reported that many environmental factors 
could induce the syndromes of thyroid autoimmunity, 
especially painless thyroiditis and Graves' disease'-'). 
Painless thyroiditis is induced within several months 
after these triggers and the duration of thyrotoxicosis 
is short. Although Graves' disease can also be induced 
by these triggers, the interval period from triggers to
the onset of thyrotoxicosis is longer than that of pain-
less thyroiditis, and it may be induced by the differ-
ence of cellular and humoral immunity between pain-
less thyroiditis and Graves' disease"". 
 Sex hormones are known to influence the immune 
system, and the fluctuation of sex hormones may be 
important factors in thyroid autoimmunity 2'' • 8' . The 
administration of goserelin acetate induces an initial 
increment of serum gonadotropin, in association with a 
corresponding increment in the serum levels of estrogen 
and progesterone""'. The prolonged administration of 
goserelin suppresses gonadotropin secretion by down 
regulation of GnRH receptors and inhibits estrogen 
and progesterone secretion. Thus, the fluctuation of 
serum levels of gonadotropin and sex hormones in-
duced by GnRH agonists may trigger the development 
of the syndromes of thyoid autoimmunity. 
 In this case, a thyroid scintigram during thyrotoxicosis 
revealed a high uptake of diffuse goiter. Moreover, 
there was positive TRAb, and she was diagnosed with 
Graves' disease. Since the onset of Graves' disease oc-
curred during the administration of goserelin and 
without other environmental factors, we speculated 
that Graves' disease might be associated with gose-
relin. Previous reports have shown two patients with 
the syndromes of thyroid autoimmunity induced by 
GnRH agonists. One was our patient in whom 
thyrotoxicosis occurred 2 months after the administra-
tion of buserelin, and the other case occurred 4 
months after leuprorelin acetate administration' ' $' . 
Both cases developed GnRH agonist-induced painless 
thyroiditis within several months. On the other hand, 
in this case, there was a longer period from starting 
goserelin to the onset of clinical thyrotoxicosis of 
Graves' disease. It is suggested that the appearance of 
thyrotoxicosis by GnRH agonist-induced Graves' dis-
ease may take longer than by painless thyroiditis, as 
with other environmental factors-induced syndromes 
of thyroid autoimmunity' - ". On the other hand, this 
patient is the first reported case of Graves' disease and 
third case of the syndromes of thyroid autoimmunity 
induced by GnRH agonists. Therefore, it may be needed 
more patients for the further examination of the rela-
tionship between GnRH agonists and the syndromes 
of thyroid autoimmunity. 
 In summary, the administration of GnRH agonists is 
thought to be one of the triggers of Graves' disease. 
Since there are many patients with subclinical thyroid 
autoimmunity, GnRH agonist-therapy should be con-
sidered carefully in these patients.
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